key: cord-0752866-6nsg9mtw authors: Mohanka, Ravi; Rao, Prashantha; Shah, Mitul; Gupte, Amit; Nikam, Vinayak; Vohra, Mihir; Kohli, Ruhi; Shrimal, Anurag; Golhar, Ankush; Panchwagh, Ameya; Kamath, Saurabh; Shukla, Akash; Patel, Priyesh; Chattopadhyay, Somnath; Chaubal, Gaurav; Shaikh, Yasmin; Dedhia, Vidhi; Sarmalkar, Shivali S.; Maghade, Ravikiran; Shinde, Kavita; Bhilare, Priyanka; Nalawade, Rohini; AS, Jacob; Shah, Samir title: Acute liver failure secondary to yellow phosphorus rodenticide poisoning: Outcomes at a center with dedicated liver intensive care and transplant unit date: 2020-10-08 journal: J Clin Exp Hepatol DOI: 10.1016/j.jceh.2020.09.010 sha: 63fff92d9fa36dd61c2840e607d12116c349ac11 doc_id: 752866 cord_uid: 6nsg9mtw Accidental or suicidal poisoning with yellow phosphorus or metal phosphides (YPMP) such as aluminum (AlP) zinc phosphide (Zn(3)P(2)) commonly cause acute liver failure (ALF) and cardiotoxicity. These are used as household, agricultural and industrial rodenticides and in production of ammunitions, firecrackers and fertilizers. In absence of a clinically available laboratory test for diagnosis or toxin measurement or an antidote, managing their poisoning is challenging even at a tertiary care center with a dedicated liver intensive care unit (LICU) and liver transplant facility. PATIENTS AND METHODS: Patients with YPMP related ALF were monitored using standardized clinical, hemodynamic, biochemical, metabolic, neurological, electrocardiography (ECG) and SOFA score and managed using uniform intensive care, treatment and transplant protocols in LICU. Socio-demographic characteristics, clinical and biochemical parameters and scores were summarized and compared between 3 groups i.e. spontaneous survivors, transplanted patients and non-survivors. Predictors of spontaneous survival and the need for liver transplant are also evaluated. RESULTS: Nineteen patients with YPMP related ALF were about 32 years old (63.2% females) and presented to us at a median of 3 (0 – 10) days after poisoning. YPMP related cardiotoxicity was rapidly progressive and fatal whereas liver transplant was therapeutic for ALF. Spontaneous survivors had lower dose ingestion (<17.5 grams), absence of cardiotoxicity, < grade 3 HE, lactate < 5.8, SOFA score < 14.5, and increase in SOFA score by < 5.5. Patients with renal failure need for CVVHDF and KCC positivity on account of PT-INR > 6.5 had higher mortality risk. Patients undergoing liver transplant and with spontaneous recovery required longer ICU and hospital stay. At median follow-up of 3.4 (2.6 – 5.5) years, all spontaneous survivors and transplanted patients are well with normal liver function. CONCLUSIONS: Early transfer to a specialized center, pre-emptive close monitoring, and intensive care and organ support with ventilation, CVVHDF, plasmapheresis and others may maximize their chances of spontaneous recovery, allow accurate prognostication and a timely liver transplant. Yellow phosphorus (YP) and metal phosphides (YPMP) such as aluminum (AlP) and zinc phosphide (Zn 3 P 2 ) are common(44 -53%) causes of accidental or suicidal rodenticide poisoning 1, 2 . They cause initial gastrointestinal symptoms but progress to systemic multi-organ failure (MOF), most prominently cardiotoxicity and acute liver failure (ALF) which are often fatal 3, 4 . This is a retrospective analysis of our outcomes in YPMP related ALF using a standardized monitoring and management protocol in a dedicated liver intensive care unit (LICU) with appropriate use of continuous veno-venous hemodiafiltration (CVVHDF) for ammonia reduction, plasmapheresis to control the systemic inflammatory response syndrome (SIRS) and liver transplant for non-recovering ALF. This is a retrospective analysis of a prospectively maintained database of all ALF patients admitted to the LICU at Global Hospital Mumbai. Study population included patients with suicidal or accidental YPMP related ALF admitted to our unit between January 2014 and December 2019. Patient demographic data, details of toxin ingestion, clinical presentation and in-hospital course, investigations, management details and outcome were recorded. The study was approved by the institutional review board. Our YPMP ALF LICU management protocol is detailed in Table 1 . Briefly, patients were monitored for clinical, laboratory and cardiac parameters. Those with grade ≥ 3 hepatic encephalopathy (HE) were electively mechanically ventilated. CVVHDF was instituted in patients with hyperammonemia, lactic acidosis or renal dysfunction. Plasmapheresis was performed in all patients except those without any evidence of systemic inflammatory response syndrome (SIRS). All patients were evaluated and prepared for liver transplant, which was performed for deterioration despite appropriate organ support. Since the composition and strength of YPMP paste was not available retrospectively, the total amount of paste ingested was used for analysis. Any arrhythmias or cardiac dysfunction was labeled as cardiotoxicity. Bone marrow toxicity was defined as drop in all 3 cell lines i.e. hemoglobin < 7 g/dl, white blood cells J o u r n a l P r e -p r o o f 7 <4000 /mm 3 and platelet count < 50,000 /mm 3 . Hypoglycemia was defined as blood sugar on admission < 70 mg/dL. Acute kidney injury (AKI) was defined per AKIN criteria 7 . Data was collected in a Microsoft Excel ® file. Delta SOFA score were calculated as the difference between the peak and initial scores and used as measure of progression of systemic toxicity. Quantitative variables were summarized using mean, standard deviation, median and range and compared using one-way ANOVA, Mann-Whitney U test or Kruskal-Wallis test as appropriate. Variances were compared using Ftest. Qualitative variables were summarized using frequency and percentages and compared using chisquare test. p value of 0.05 was considered significant. For quantitative variables with significant differences receiver operating characteristic (ROC) curves were used to calculate area under the curve (AUC), optimum cut-offs and their sensitivity and specificity. Multivariate regression analysis was done to identify risk factors for mortality. All statistical analyses were done using IBM SPSS 16 ® . Out of 199 ALF patients managed in our LICU between January 2014 and December 2019, 23 (11.6%) had YPMP related ALF. Four patients were discharged or transferred to another hospital against medical advice without completion of adequate treatment; their outcomes were not available and were excluded from analysis. The study populations consisting of 19 patients were all transferred from other hospitals at a median of 3 (0 -10) days after toxin ingestion. Patients were divided into 3 groups: The mean age of patients was 32 years ± 9.6, more commonly females (63.2%). More females survived spontaneously, and more men underwent a transplant, differences being similar across groups. Spontaneous survivors consumed significantly lesser YPMP compared to others, less than 17.5 grams being favorable. No patients had history of pre-existing liver disease, consumption of other hepatotoxic drugs or food supplements at the same time. Admission and peak bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, gamma-glutamyl transpeptidase (GGTP), hypoglycemia, PT-INR (before plasmapheresis), creatinine, arterial ammonia and lactate (before CVVHDF) and lowest fibrinogen (before FFP or cryoprecipitate transfusion) were similar across groups. Similarly, peak bilirubin, AST, ALT, alkaline phosphatase, GGTP, PT-INR, creatinine and arterial ammonia were similar although spontaneous survivors had significantly lower peak lactate (<5.8 mg/dL) compared to others. Four (21.1%) patients had cardiotoxicity, none among spontaneous survivors. Three (42.9%) nonsurvivors, one each had supra-ventricular tachycardia, ventricular tachycardia and cardiomyopathy. While they also had ALF, rapidly progressive cardiotoxicity caused mortality. One patient developed early myocardial suppression (ejection fraction decreased from 60% to 30%) and cardiogenic shock that improved with resuscitation and levosimendan. She then underwent a successful DDLT. Another transplant patient had severe pulmonary hypertension with right heart dysfunction and preserved left ventricular contractility, requiring inhaled nitric oxide and milrinone perioperatively, which was tapered off postoperatively (this case was not included as cardiotoxicity). AKI and CVVHDF Ten (52.6%) patients developed AKI which was significantly higher in non-survivors compared to spontaneous survivors, but not different from transplant patients. Fifteen patients (78.9%) needed CVVHDF, including all transplant patients and non-survivors which was significantly higher compared to spontaneous survivors. The indication for CVVHDF was renal in 3 (20%), hyperammonemia alone in 3 J o u r n a l P r e -p r o o f 9 (20%), severe lactic acidosis in 2 (13.3%), renal with hyperammonemia in 2 (13.3%), renal with lactic acidosis in 3 (20%) and all these three indications in 2 (13.3%) patients. MOF, SOFA score and plasmapheresis Six (31.6%) patients developed bone marrow suppression, similar across groups that recovered spontaneously. One patient required filgrastim before transplant. One spontaneous survivor and 2 nonsurvivors required platelet transfusions based on TEG for bleeding whereas 4 patients required platelets during transplant. No patients had gastrointestinal toxicity or pancreatitis. Admission SOFA score was similar between groups, but peak (< 14.5) and delta (< 5.5) SOFA scores were lower in spontaneous survivors compared to others, probably indicating slower progression to MOF. Fifteen (78.9%) patients underwent median of 3 (1 -4) cycles of plasmapheresis, which was similar between groups. Three out of 4 patients who did not undergo plasmapheresis did not have any evidence of SIRS and one patient was too unstable for it. None of the patients had any morbidity related to plasmapheresis. At presentation, all patients had transaminitis and coagulopathy, 16 (84.2%) had jaundice and 12 (63.2%) had HE. All patients developed HE at some point; all non-survivors progressed to develop ≥ grade 3 HE, which was significantly higher compared to others. Seventeen (89.5%) patients had hyperacute presentation with jaundice to encephalopathy interval 4.1 ± 2.3 days, which was similar across groups. Ingestion to encephalopathy interval (IEI) was shortest in non-survivors and longest in spontaneous survivors, although not significantly different. There was no mortality due to raised ICP or its complications. MELD score on admission (29.9 ± 12.6) and peak (35.2 ± 8) were similar across groups. All non-survivors and transplant patients met KCC compared to only 4 (57.1%) spontaneous survivors (p = 0.013). Most 14 (73.7%) patients met KCC on account of PT-INR > 6.5. All patients with encephalopathy meeting KCC were considered for transplant. All patients in LT and NS groups met KCC and were offer a transplant. In NS group, 1 patient rapidly deteriorated after admission and expired, 2 patients developed cardiac side effects and deteriorated of which 1 had a prospective living related donor under evaluation and 1 was waiting for a deceased donor organ, 2 other patients developed progressive MOF and expired, 2 patients did not undergo transplant due to financial constraints. In the SS group, 4 (57.1%) patients fulfilling KCC were offered a transplant although they improved with medical J o u r n a l P r e -p r o o f management. Five patients underwent liver transplants, 2 living donor liver transplant (LDLT) and 3 DDLT at 6.2 ± 5.1 days from admission. In patients undergoing transplant, CVVHDF was continued during the transplant. Intraoperatively hepatomegaly with soft consistency and pale color was observed. Histopathology of explanted livers showed mild to severe balloon degeneration and bridging necrosis and minimal to marked portal infiltration in all patients and diffuse micro and macro steatosis in 3 patients and none in 2 patients. There was no mortality after undergoing a liver transplant in our series. Three patients had post-operative ventilator associated gram-negative pneumonia and one had and intra-abdominal infection collection, all of whom responded to antibiotics. Two patients had vocal cord palsy that recovered with speech therapy. One patient each had an early bile leak and stricture, both responding well to endoscopic biliary stenting. Three patients had non-compliance related acute cellular rejection (ACR), one of them had cholestatic steroid resistant ACR that responded to thymoglobulin, also required endoscopic biliary stenting for a late stricture and is currently hospitalized and recovering from a COVID-19 infection. The other two responded to steroid boluses, one of them also had late hepatic artery thrombosis with spontaneous collateralization. Two patients had CMV infection on follow-up that were treated successfully. The ICU and hospital stay were significantly longer for transplant patients, because of initial trial of supportive management and slower recovery after transplant, whereas it was shortest for non-survivors, probably due to rapidly progressive systemic toxicity and fatal outcome. YPMP are highly soluble in lipids and bile and get rapidly absorbed through the skin, mucosal, respiratory, and gastrointestinal (GI) linings. On exposure to environment or contact with gastric acid they release phosphene (PH 3 ) gas which is highly corrosive 8 . They are rapidly distributed systemically in 2 -3 hours, predominantly in the liver (69 -73%), heart (12%), kidneys (4%) and smaller quantities (< 1%) in pancreas, spleen, brain and other organs causing their toxicity, which could explain their predilection for hepatotoxicity and cardiotoxicity 9 . YPMP are cheaply, widely and freely available over the counter as household and agricultural rodenticides in the Indian sub-continent and as components of firecrackers in other countries with varied composition and strength (figure 1, table 4) 10, 11 . In our series suicidal ingestion of raw Zn 3 P 2 rodenticide paste caused toxicity, consistent with reports from South India and different from North India where AlP toxicity is most common, which may be due to referral bias 15 . Impulsive suicidal consumption with alcohol or water (as death is believed to be painless), accidental consumption by children (as directions for use include applying the paste on bread) and by adults (mistaken for toothpaste) have been reported 16 . Lethal dose of 13.42 ± 7.069 grams of household rodenticide has been reported, similar to spontaneous survival with dose <17.5 grams in our series 17 . The demographic profile of our patients is consistent with other studies 18 .Clinical manifestations of YPMP poisoning may be divided into 3 phases (Table 5) , which are consistent with our series, except very low rate of GI toxicity in our patients, probably due to late presentation beyond the first two phases (at about 3 days) 19 . In our series, all patients had ALF with HE, none had cholestatic presentation. Other causes of ALF such as viral hepatitis, autoimmune, drug induced liver injury (DILI) and others should be ruled out if the history of poisoning is unavailable or unclear. USG showed hepatomegaly with fatty liver in all cases, consistent with literature, although not specific for YPMP 22, 23 . A high index of suspicion should be kept and specific history of YPMP ingestion elicited in all poisoning cases with GI symptoms, cardiotoxicity or hepatotoxicity as details by the patient or their families may be often incomplete or inaccurate 24 . They should be requested to bring the empty / remaining tube or its picture. Milk or fatty foods may promote phosphorus absorption therefore a high-carbohydrate, high-protein, lowfat or no-fat diet with supplementary intravenous glucose and vitamins is preferred, except in patients on high dose inotropes where oral feeds are avoided or in HE where naso-gastric feeding is preferred 29 . Proton pump inhibitors or H2 receptor antagonists inhibit PH 3 release by reducing gastric acid secretion and for ulcer prophylaxis. Patients presenting within few hours of ingestion may benefit from cautious gastric decontamination 30 . In our series only 1 patient was admitted within 24 hours of ingestion where normal saline gastric lavage was done. Additives such as potassium permanganate, charcoal, activated charcoal and copper sulphate may further hasten disintegration and increase toxicity and therefore not advised 31, 32 . Metabolic acidosis is corrected using sodium bicarbonate infusion 33 . Lactulose is used to reduce ammonia load in ALF patients with constipation 34 . Cholestyramine, UDCA, and sertraline may be used for cholestatic presentation 35 . Rifaximin, s-adenosyl methionine (SAM), l-ornithine l-aspartate (LOLA), steroids and exchange transfusion have not shown benefit 36 . Inconsistent benefit of NAC has been reported in ALF, especially with early (within 6 hours) use, although it may be confounded by the benefit of early gastric lavage 37 . NAC being a safe and low-cost drug is part of our protocol 38 . Pre-emptive vitamin K (phytomenadione) (10 -30 mg x 5 days) or fresh frozen plasma (FFP) has been recommended to reduce bleeding risk or platelets transfusion for thrombocytopenia (bone J o u r n a l P r e -p r o o f 13 marrow toxicity) 39 . We used vitamin K 10mg for 3 days and in patients with PT-INR > 2. Coagulopathy was corrected for nasal bleeding in one patient, guided by coagulation parameters and TEG. Consensus for CVVHDF use in ALF is evolving 40 Most patients with mortality them had high dose of ingestion and MOF in our series, with no losses after liver transplant. Early HE has been reported to have poorer outcomes, although IHE was shortest in nonsurvivors, it was not significant from other groups in our series 43 .Spontaneous survivors had lower dose ingestion (< 17.5 grams), absence of cardiotoxicity, 6.5 had higher mortality risk. Preparation for an emergency orthotopic DDLT or LDLT (not auxiliary transplant) should be initiated early although optimal criteria and timing for transplant are not well known 44 . Development of HE has been suggested as an indication for transplant 19, 27 . In our series all spontaneous survivors also had HE and only ≥ grade 3 HE was associated with poor outcomes. We suggest offering transplant to patients with ≥ grade 3 HE. KCC and NHSBT ALF criteria have also been used to offer transplant, although they have not been validated for YPMP poisoning. In our series, 43% patients survived spontaneously despite meeting KCC. In absence of HE, markers of severe acute liver injury (ALI) such as PT-INR > 6.0, MELD score > 37, persistently elevated serum lactate despite resuscitation and with plasmapheresis PT-INR > 2.5, at least 12 hours after second cycle have been proposed for transplantation 27 In absence of a clinically available laboratory test for diagnosis or toxin measurement or an antidote, early transfer to a specialized center, pre-emptive close monitoring, intensive care and organ support with ventilation, CVVHDF, plasmapheresis and others may maximize their chances of spontaneous recovery, allow accurate prognostication and a timely liver transplant. Prevention of toxicity by restricting access to this toxin to public, banning its sale, storage or promotion of alternative safer rodenticides have been suggested. Safer packaging which is difficult to open for kids and prominent labeling of toxicity may be useful 47 . Awareness of its severe toxicity and high lethality in very small quantities among public, people handling the toxin and clinicians could be helpful too. We acknowledge the inherent biases in this retrospective case series and inability to draw conclusions about causation or treatment efficacy. Since the toxicity is more common in the Indian sub-continent, a multi-center study from this region would be able to better define optimal management including the role of plasmapheresis and develop criteria for liver transplant for YPMP toxicity. The authors have nothing to declare. No grant support or any kind of financial assistance from other institute. • All YPMP ALF patients are monitored in the LICU for 3 -5 days after ingestion and nursed in 30degree head elevated position. • Patients are assessed for clinical parameters especially for liver, cardiac and neurotoxicity with hourly assessment for HE and pupillary reflexes and continuously monitored for vital parameters and electrocardiography (ECG). • Gastric lavage is done without any additives for patients presenting within 24 hours. A nasogastric tube is used for gastric decompression in patients with HE. • Patients with HE ≥ grade 3are electively sedated and intubated. pCO 2 is maintained between 30-35 mm Hg.If raised intracranial pressure (ICP) is suspected, optic nerve diameter, reverse jugular oxygen saturation, trans-cranial doppleror CT brain is done. Direct intracranial pressure monitoring may be done very selectively.Standard protocols for managing raised ICP are followed including mannitol, thiopentone and others. • Fluid intake, output and balance are monitored hourly, serum electrolytes, acidosis, ammonia and lactate are monitored 2 nd hourly using arterial blood gases (ABG) and corrected appropriately. Serum sodium is maintained between 145-150 meq/dl. • Blood glucose is monitored 6 hourly and corrected as required. • Chest X-ray, abdominal ultrasonography (USG) and 12-lead ECG and echocardiogram (ECHO) are done on admission. A cardiologist is consulted for suspected cardiotoxicity. • Sequential organ failure assessment (SOFA) score is calculated on admission and daily. • Awake patients are given high-carbohydrate, high-protein, low-fat or no-fat diet with supplementary intravenous dextrose and multi-vitamins. Patients with ≥ grade 2 HE or high dose inotropes are kept nil per orally (NPO). • N-acetylcysteine (NAC) is given at 100 mg/kg IV over 24 hours for 5 days. • Prophylactic antimicrobials (ceftriaxone + sulbactam) and antifungals (fluconazole) are used in patients with HE, high lactate, or SIRS. • Lactulose and rifaximin are given to patients with HE, not on CVVHDF. • Patients with PT-INR > 2 are given vitamin K 10 mg IV for 3 days. o May be similar to that described in phase I o May present with ischemic heart disease or simulate acute myocardial infarction leading to reduced contractility and cardiogenic shock due to direct toxicity on myocardium or conduction fibers. o Acute pulmonary edema has also been reported. • Renal toxicity (25%): uremia, oliguria, albuminuria, hematuria and rarely phosphorescent urine, may be due to hypovolemic shock or direct toxicity. • Bone marrow toxicity: neutropenia is common, although any cell lines could be affected. • Central nervous system (CNS) toxicity: headache, restlessness, irritability, tinnitus, confusion, deafness, impaired vision, convulsions, psychosis, hallucinations, delirium, drowsiness, lethargy or coma.Some of these may be due to hepatic encephalopathy or direct CNS toxicity. • Multi-organ failure MOF (25% patients) • Extensive hemolysis and / or rhabdomyolysis have been associated with poor prognosis. Clinical Profile and Outcomes of Rodenticide Poisoning in Tertiary Care Hospital Rodenticidal Poisoning in a Tertiary Centre in North Kerala Zinc phosphide intoxication symptoms: analysis of 20 cases Rodenticide-induced hepatotoxicity Early indicators of prognosis in fulminant hepatic failure Liver Advisory Group on behalf of National Health Service Blood and Transplant (NHSBT) POLICY POL195/7 Liver Transplantation: Selection Criteria and Recipient Registration Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury Profile of Rat Killer Poisoning Cases in a Tertiary Care Hospital at Mysore Histopathological Profile in Fatal Yellow Phosphorous Poisoning White phosphorus poisoning by oral ingestion of firecrackers or little devils: current experience in Ecuador Ingestion of fireworks: rare cause of poisoning in children Impact on Morbidity & Mortality by Rodenticidal Poisoning. Indian Medical Gazette What is the real cause of hepatic dysfunction after zinc phosphide containing rodenticide poisoning? A case report of zinc phosphide poisoning: complicated by acute renal failure and tubulo interstitial nephritis Rodenticide poisoning: Literature review and management A rare cause of poisoning in childhood: Yellow phosphorus Liver Damage: A View in South Indian Patients of Tertiary Care Center Clinical spectrum of yellow phosphorous poisoning in a tertiary care centre in South India: A case series Acute liver failure due to zinc phosphide containing rodenticide poisoning: Clinical features and prognostic indicators of need for liver transplantation Clinical profile and outcome of rodenticide poisoning in patients admitted to a tertiary care teaching hospital in Mysore, Karnataka. India Acute yellow phosphorus poisoning causing fulminant hepatic failure with parenchymal hemorrhages and contained duodenal perforation Cholestatic presentation of yellow phosphorus poisoning A Case on Suicidal Poisoning Associated with Ratol and a Perspective on Yellow Phosphorus Poisoning Ventricular Arrhythmia Due to Yellow Phosphorus Poisoning Clinical Characteristics of zinc phosphide poisoning in Thailand Selective myelosuppression following yell ow phosphorus ingestion Liver transplant society of India (LTSI) consensus guidelines for management of acute liver failure (ALF) secondary to Yellow Phosphorous Poisoning Should ratol paste be banned? Critical Care Toxicology -Diagnosis and Management of the Critically Poisoned Patient Acute yellow phosphorus poisoning Aluminium and zinc phosphide poisoning Acute phosphorus poisoning Phosphide poisoning: a review of literature Intensive care management of children with acute liver failure Acute hepatotoxicity from ingestion of yellow phosphoruscontaining fireworks A boon for Yellow Phosphorus-Induced Acute Liver Failure? A Case Report Efficacy of Early N-Acetylcysteine in Rat Killer Paste Poisoning Acute yellow phosphorus poisoning -retrospective analysis in a tertiary care centre Successful Outcomes In Rodenticide Poisoning Containing Yellow Phosphorus Paste And Zinc Phosphide By Vitamin K, Early Plasmapheresis & L-Ornithine-L-Aspartate Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration Acute pulmonary edema and cardiac failure due to zinc phosphide ingestion Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: A placebo controlled clinical trial Acute YP poisoning from pesticide pastes A Case on suicidal poisoning associated with ratol and a perspective on yellow phosphorus poisoning Acute aluminium phosphide poisoning: can we predict mortality? Clinical and pathological findings on intoxication by Yellow Phosphorus after ingesting firework cracker: A rare case of autopsy Successful Treatment of Acute Liver Failure due to Yellow Phosphorus Ingestion in a Rural, Low Resource Setting The authors would like to thank Dr. Srinivas Reddy for helping to develop this article manuscript and providing a valuable factual review. Hospital admission (days) 11.1 ± 7.9 12.3 ± 9.2 21 ± 2 6.1 ± 3.5